Re-evaluation of dipeptidyl peptidase-4 inhibitors in patients with heart failure and diabetes mellitus
Authors' conclusion
DPP-4i may reduce all-cause mortality in heart failure patients in subgroups of women and HFpEF and has a high coronary safety profile.
Study context
- Population
- Patients with HF and DM
- Comparison
- DPP-4i vs control
- Outcome
- All-cause mortality, CV death, hospitalization for HF
Pooled result
As reported in the abstract
- DPP-4i did not reduce the risk of all-cause death, CV death or hospitalization for HF
Further pooled results
All-cause mortality, subgroup of trials with >40% female patients
| OR (95% CI) | P value | ||
|---|---|---|---|
| DPP-4i | 0.30 (0.16–0.58) | P = 0.0003 | |
| 0.10.31310Odds ratio (log scale) |
All-cause mortality, subgroup of trials with >20% patients with heart failure with preserved ejection fraction (HFpEF)
| OR (95% CI) | P value | ||
|---|---|---|---|
| DPP-4i | 0.34 (0.19–0.60) | P = 0.0003 | |
| 0.20.5125Odds ratio (log scale) |
Changes in left ventricular ejection fraction (LVEF) and left ventricular end-diastolic volume (LVEDV)
- No statistical differences between the 2 groups
Safety
- DPP-4i did not alter the risk of acute coronary syndrome and acute MI
Original publication
Re-evaluation of dipeptidyl peptidase-4 inhibitors in patients with heart failure and diabetes mellitus. Diabetes Res Clin Pract. Published 24 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →